Subscribe To

Price Alert Latest News Economic Calendar News

CLNN / HC Wainwright Initiates Coverage On This Nanocrystals Stock

H.C. Wainwright initiated coverage on Clene Inc (NASDAQ: CLNN) with a Buy rating and a $16 price target. Clene is focused on the development of novel clean-surfaced nanotechnologies consisting of transition element nanocrystals for central nervous disorders, such as. Read More

Demo Live Account See Partner Details

Content Topics

Wainwright

Initiates

Coverage

This

Nanocrystals

Stock

CLNN

Posted: Jul 18 2022, 15:15

Author Name: Benzinga

CLNN News

By GlobeNewsWire
August 30, 2023

Clene to Present at Upcoming September Conferences

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary

By Zacks Investment Research
May 12, 2023

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $

By GlobeNewsWire
March 8, 2023

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

Webcast set for 7:30 a.m. ET on March 9 Webcast set for 7:30 a.m. ET on March 9

By GlobeNewsWire
August 30, 2022

Clene to Present at Upcoming September Investor Conferences

SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary

By The Motley Fool
July 18, 2022

Why Shares of Clene Jumped 11.8% on Monday

The company's lead therapy has shown progress against ALS in preliminary trials.

By Benzinga
July 18, 2022

HC Wainwright Initiates Coverage On This Nanocrystals Stock

H.C. Wainwright initiated coverage on Clene Inc (NASDAQ: CLNN) with a Buy rating and a $16 price target. Clene is focused on the development of

By InvestorPlace
July 14, 2022

Why Is Clene (CLNN) Stock Soaring 23% Today?

Clene (CLNN) stock is heading higher on Thursday following the release of data from a long-term clinical trial of CNM-Au8. The post Why Is Clene (CLNN

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.